Trials / Terminated
TerminatedNCT03862846
A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy
An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Reneo Pharma Ltd · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REN001 | Once daily |
Timeline
- Start date
- 2019-05-10
- Primary completion
- 2020-04-23
- Completion
- 2020-04-23
- First posted
- 2019-03-05
- Last updated
- 2020-07-16
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03862846. Inclusion in this directory is not an endorsement.